[Interview] Shaping European AI Regulation To Secure Global Leadership In Healthcare

However, there is a serious concern that the European Union regulatory environment will become a barrier for AI innovation, leading to delays in the adoption of AI which can make the European healthcare sector less competitive globally.

To address such risks, the European Commission published three whitepapers proposing an overarching regulatory framework for the widespread application of Artificial Intelligence to the European ecosystem. TietoEVRY, a global IT and software company, recently published its position on the proposed AI regulation, as an effort to augment it with a more pragmatic, entrepreneurial, and innovative view.

I reached out to Dr. Christian Guttmann, VP and Head of Global AI & Data at TietoEVRY, and Executive Director of the Nordic AI Institute, and an established thought leader in the area of industrial AI adoption, to learn more about the new regulatory initiative by European Commission, TietoEVRY’s vision of it, and the impact the regulation will have on the European healthcare industry. 

Andrii: What’s the current role of AI in the European Life Sciences and Healthcare industries, and how would you describe its near term adoption trajectory? 

AI applications are just at the beginning of creating a major impact on the Life Sciences and Healthcare industries. All aspects of the end-to-end lifecycle will be influenced or changed. Take the pharmaceutical domain as an example. The speed of identification of effective molecules on pathogens can be drastically improved (therefore saving a lot of time) all the way to effective assessment of real-world evidence through data on online patient platforms and wearable devices.